- •Preface to the First Edition
- •Preface to the Second Edition
- •Contents
- •Diagnostic Challenges
- •Expert Centers
- •Patient Organizations
- •Clinical Trials
- •Research in Orphan Lung Diseases
- •Orphan Drugs
- •Orphanet
- •Empowerment of Patients
- •Conclusions
- •References
- •Introduction
- •Challenges to Overcome in Order to Undertake Quality Clinical Research
- •Lack of Reliable Data on Prevalence
- •Small Number of Patients
- •Identifying Causation/Disease Pathogenesis
- •Disease Complexity
- •Lack of Access to a Correct Diagnosis
- •Delay in Diagnosis
- •Challenges But Not Negativity
- •Some Success Stories
- •The Means to Overcome the Challenges of Clinical Research: Get Bigger Numbers of Well-Characterized Patients
- •The Importance of Patient Organizations
- •National and International Networks
- •End Points for Trials: Getting Them Right When Numbers Are Small and Change Is Modest
- •Orphan Drug Development
- •Importance of Referral Centers
- •Looking at the Future
- •The Arguments for Progress
- •Concluding Remarks
- •References
- •3: Chronic Bronchiolitis in Adults
- •Introduction
- •Cellular Bronchiolitis
- •Follicular Bronchiolitis
- •Respiratory Bronchiolitis
- •Airway-Centered Interstitial Fibrosis
- •Proliferative Bronchiolitis
- •Diagnosis
- •Chest Imaging Studies
- •Pulmonary Function Testing
- •Lung Biopsy
- •Mineral Dusts
- •Organic Dusts
- •Volatile Flavoring Agents
- •Infectious Causes of Bronchiolitis
- •Idiopathic Forms of Bronchiolitis
- •Connective Tissue Diseases
- •Organ Transplantation
- •Hematopoietic Stem Cell Transplantation
- •Drug-Induced Bronchiolitis
- •Treatment
- •Constrictive Bronchiolitis
- •Follicular Bronchiolitis
- •Airway-Centered Interstitial Fibrosis
- •Proliferative Bronchiolitis
- •References
- •Background and Epidemiology
- •Pathophysiology
- •Host Characteristics
- •Clinical Manifestations
- •Symptoms
- •Laboratory Evaluation
- •Skin Testing
- •Serum Precipitins
- •Eosinophil Count
- •Total Serum Immunoglobulin E Levels
- •Recombinant Antigens
- •Radiographic Imaging
- •Pulmonary Function Testing
- •Histology
- •Diagnostic Criteria
- •Historical Diagnostic Criteria
- •Rosenberg and Patterson Diagnostic Criteria
- •ISHAM Diagnostic Criteria
- •Cystic Fibrosis Foundation Diagnostic Criteria
- •General Diagnostic Recommendations
- •Allergic Aspergillus Sinusitis (AAS)
- •Natural History
- •Treatment
- •Corticosteroids
- •Antifungal Therapy
- •Monoclonal Antibodies
- •Monitoring for Treatment Response
- •Conclusions
- •References
- •5: Orphan Tracheopathies
- •Introduction
- •Anatomical Considerations
- •Clinical Presentation
- •Etiological Considerations
- •Idiopathic Subglottic Stenosis
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Introduction and Clinical Presentation
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheomalacia
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheobronchomegaly
- •Introduction
- •Clinical Features
- •Pathophysiology
- •Pulmonary Function Studies
- •Imaging Studies
- •Treatment
- •Tracheopathies Associated with Systemic Diseases
- •Relapsing Polychondritis
- •Introduction
- •Clinical Features
- •Laboratory Findings
- •Pulmonary Function and Imaging Studies
- •Treatment
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Tracheobronchial Amyloidosis
- •Introduction
- •Clinical Features
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Sarcoidosis
- •Introduction
- •Pulmonary Function Studies
- •Imaging Studies
- •Bronchoscopy
- •Treatment
- •Orphan Tracheopathies: Conclusions
- •References
- •6: Amyloidosis and the Lungs and Airways
- •Introduction
- •Diagnosis and Evaluation of Amyloidosis
- •Systemic AA Amyloidosis
- •Systemic AL Amyloidosis
- •Amyloidosis Localised to the Respiratory Tract
- •Laryngeal Amyloidosis
- •Tracheobronchial Amyloidosis
- •Parenchymal Pulmonary Amyloidosis
- •Pulmonary Amyloidosis Associated with Sjögren’s Disease
- •Conclusions
- •References
- •Introduction
- •Pathophysiology
- •Genetic Predisposition
- •Immune Dysregulation
- •Epidemiology
- •Incidence and Prevalence
- •Triggering Factors
- •Clinical Manifestations
- •General Symptoms
- •Pulmonary Manifestations
- •Ear, Nose, and Throat (ENT) Manifestations
- •Neurological Manifestations
- •Skin Manifestations
- •Cardiac Manifestations
- •Gastrointestinal Involvement
- •Renal Manifestations
- •Ophthalmological Manifestations
- •Complementary Investigations
- •Diagnosis
- •Diagnostic Criteria
- •Prognosis and Outcomes
- •Phenotypes According to the ANCA Status
- •Treatment
- •Therapeutic Strategies
- •Remission Induction
- •Maintenance Therapy
- •Other Treatments
- •Prevention of AEs
- •Conclusions
- •References
- •8: Granulomatosis with Polyangiitis
- •A Brief Historical Overview
- •Epidemiology
- •Pathogenesis
- •Clinical Manifestations
- •Constitutional Symptoms
- •Ear, Nose, and Throat (ENT) Manifestations
- •Pulmonary Manifestations
- •Kidney and Urological Manifestations
- •Kidney Manifestations
- •Urological Manifestations
- •Neurological Manifestations
- •Peripheral Nervous System (PNS) Manifestations
- •Central Nervous System (CNS) Manifestations
- •Spinal Cord and Cranial Nerve Involvement
- •Skin and Oral Mucosal Manifestations
- •Eye Manifestations
- •Cardiac Involvement
- •Gastrointestinal Manifestations
- •Gynecological and Obstetric Manifestations
- •Venous Thrombosis and Other Vascular Events
- •Other Manifestations
- •Pediatric GPA
- •Diagnosis
- •Diagnostic Approach
- •Laboratory Investigations
- •Biology
- •Immunology
- •Pathology
- •Treatment
- •Glucocorticoids
- •Cyclophosphamide
- •Rituximab
- •Other Current Induction Approaches
- •Other Treatments in GPA
- •Intravenous Immunoglobulins
- •Plasma Exchange
- •CTLA4-Ig (Abatacept)
- •Cotrimoxazole
- •Other Agents
- •Principles of Treatment for Relapsing and Refractory GPA
- •Outcomes and Prognostic Factors
- •Survival and Causes of Deaths
- •Relapse
- •Damage and Disease Burden on Quality of Life
- •Conclusions
- •References
- •9: Alveolar Hemorrhage
- •Introduction
- •Clinical Presentation
- •Diagnosis (Table 9.1, Fig. 9.3)
- •Pulmonary Capillaritis
- •Histology (Fig. 9.4)
- •Etiologies
- •ANCA-Associated Small Vessel Vasculitis: Granulomatosis with Polyangiitis (GPA)
- •ANCA-Associated Small Vessel Vasculitis: Microscopic Polyangiitis
- •Isolated Pulmonary Capillaritis
- •Systemic Lupus Erythematosus
- •Antiphospholipid Antibody Syndrome
- •Anti-Basement Membrane Antibody Disease (Goodpasture Syndrome)
- •Lung Allograft Rejection
- •Others
- •Bland Pulmonary Hemorrhage (Fig. 9.5)
- •Histology
- •Etiologies
- •Idiopathic Pulmonary Hemosiderosis
- •Drugs and Medications
- •Coagulopathy
- •Valvular Heart Disease and Left Ventricular Dysfunction
- •Other
- •Histology
- •Etiologies
- •Hematopoietic Stem Cell Transplantation (HSCT)
- •Cocaine Inhalation
- •Acute Exacerbation of Interstitial Lung Disease
- •Acute Interstitial Pneumonia
- •Acute Respiratory Distress Syndrome
- •Miscellaneous Causes
- •Etiologies
- •Pulmonary Capillary Hemangiomatosis
- •Treatment
- •Conclusions
- •References
- •Takayasu Arteritis
- •Epidemiology
- •Pathologic Features
- •Pathogenesis
- •Clinical Features
- •Laboratory Findings
- •Imaging Studies
- •Therapeutic Management
- •Prognosis
- •Behçet’s Disease
- •Epidemiology
- •Pathologic Features
- •Pathogenesis
- •Diagnostic Criteria
- •Clinical Features
- •Pulmonary Artery Aneurysm
- •Pulmonary Artery Thrombosis
- •Pulmonary Parenchymal Involvement
- •Laboratory Findings
- •Imaging Studies
- •Therapeutic Management
- •Treatment of PAA
- •Treatment of PAT
- •Prognosis
- •References
- •Introduction
- •Portopulmonary Hypertension (PoPH)
- •Epidemiology and Risk Factors
- •Molecular Pathogenesis
- •PoPH Treatment
- •Hepatopulmonary Syndrome (HPS)
- •Epidemiology and Risk Factors
- •Molecular Pathogenesis
- •HPS Treatment
- •Conclusion
- •References
- •12: Systemic Sclerosis and the Lung
- •Introduction
- •Risk factors for SSc-ILD
- •Genetic Associations
- •Clinical Presentation of SSc-ILD
- •Pulmonary Function Tests (PFTs)
- •Imaging
- •Management
- •References
- •13: Rheumatoid Arthritis and the Lungs
- •Introduction
- •Epidemiology
- •Risk Factors for ILD (Table 13.3)
- •Pathogenesis
- •Clinical Features and Diagnosis
- •Treatments
- •Prognosis
- •Epidemiology
- •Risk Factors
- •Clinical Features, Diagnosis, and Outcome
- •Subtypes or RA-AD
- •Obliterative Bronchiolitis
- •Bronchiectasis
- •COPD
- •Cricoarytenoid Involvement
- •Pleural Disease
- •Conclusion
- •References
- •Introduction
- •Systemic Lupus Erythematosus
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Pleural Disease
- •Shrinking Lung Syndrome
- •Thrombotic Manifestations
- •Interstitial Lung Disease
- •Other Pulmonary Manifestations
- •Prognosis
- •Sjögren’s Syndrome
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Airway Disorders
- •Lymphoproliferative Disease
- •Interstitial Lung Disease
- •Prognosis
- •Mixed Connective Tissue Disease
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations
- •Pulmonary Hypertension
- •Interstitial Lung Disease
- •Prognosis
- •Myositis
- •Epidemiology
- •Pathophysiology
- •Pulmonary Manifestations and Treatments
- •Interstitial Lung Disease
- •Respiratory Muscle Weakness
- •Other Pulmonary Manifestations
- •Prognosis
- •Other Therapeutic Options in CTD-ILD
- •Lung Transplantation
- •Conclusion
- •References
- •Introduction
- •Diagnostic Criteria
- •Controversies in the Diagnostic Criteria
- •Typical Clinical Features
- •Disease Progression and Prognosis
- •Summary
- •References
- •Introduction
- •Histiocytes and Dendritic Cells
- •Introduction
- •Cellular and Molecular Pathogenesis
- •Pathology
- •Clinical Presentation
- •Treatment and Prognosis
- •Erdheim-Chester Disease
- •Epidemiology
- •Cellular and Molecular Pathogenesis
- •Histopathology and Immunohistochemistry
- •Clinical Presentation
- •Investigation/Diagnosis
- •Chest Studies
- •Cardiovascular Imaging
- •CNS Imaging
- •Bone Radiography
- •Other Imaging Findings and Considerations
- •Disease Monitoring
- •Pathology
- •Management/Treatment
- •Prognosis
- •Rosai-Dorfman Destombes Disease
- •Epidemiology
- •Etiology/Pathophysiology
- •Histopathology and Immunohistochemistry
- •Clinical Presentation
- •Investigation/Diagnosis
- •Management/Treatment
- •Prognosis
- •Conclusions
- •Diagnostic Criteria for Primary Histiocytic Disorders of the Lung
- •References
- •17: Eosinophilic Pneumonia
- •Introduction
- •Eosinophil Biology
- •Physiologic and Immunologic Role of Eosinophils
- •Release of Mediators
- •Targeting the Eosinophil Cell Lineage
- •Historical Perspective
- •Clinical Presentation
- •Pathology
- •Diagnosis
- •Eosinophilic Lung Disease of Undetermined Cause
- •Idiopathic Chronic Eosinophilic Pneumonia
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Bronchoalveolar Lavage
- •Lung Function Tests
- •Treatment
- •Outcome and Perspectives
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Bronchoalveolar Lavage
- •Lung Function Tests
- •Lung Biopsy
- •Treatment and Prognosis
- •Eosinophilic Granulomatosis with Polyangiitis
- •History and Nomenclature
- •Pathology
- •Clinical Features
- •Imaging
- •Laboratory Studies
- •Pathogenesis
- •Diagnosis
- •Treatment and Prognosis
- •Long-Term Outcome
- •Hypereosinophilic Syndrome
- •Pathogenesis
- •Clinical and Imaging Features
- •Laboratory Studies
- •Treatment and Prognosis
- •Eosinophilic Pneumonias of Parasitic Origin
- •Tropical Eosinophilia [191]
- •Ascaris Pneumonia
- •Eosinophilic Pneumonia in Larva Migrans Syndrome
- •Strongyloides Stercoralis Infection
- •Eosinophilic Pneumonias in Other Infections
- •Allergic Bronchopulmonary Aspergillosis
- •Pathogenesis
- •Diagnostic Criteria
- •Biology
- •Imaging
- •Treatment
- •Bronchocentric Granulomatosis
- •Miscellaneous Lung Diseases with Associated Eosinophilia
- •References
- •Introduction
- •Pulmonary Langerhans’ Cell Histiocytosis
- •Epidemiology
- •Pathogenesis
- •Diagnosis
- •Clinical Features
- •Extrathoracic Lesions
- •Pulmonary Function Tests
- •Chest Radiography
- •High-Resolution Computed Tomography (HRCT)
- •Bronchoscopy and Bronchoalveolar Lavage (BAL)
- •Lung Biopsy
- •Pathology
- •Treatment
- •Course and Prognosis
- •Case Report I
- •Introduction
- •Epidemiology
- •Clinical Features
- •Histopathological Findings
- •Radiologic Findings
- •Prognosis and Therapy
- •Desquamative Interstitial Pneumonia
- •Epidemiologic and Clinical Features
- •Histopathological Findings
- •Radiological Findings
- •Prognosis and Therapy
- •Conclusion
- •References
- •19: Lymphangioleiomyomatosis
- •Introduction
- •Pathogenesis
- •Presentation
- •Prognosis
- •Management
- •General Measures
- •Parenchymal Lung Disease
- •Pleural Disease
- •Renal Angiomyolipoma
- •Abdominopelvic Lymphatic Disease
- •Pregnancy
- •Tuberous Sclerosis
- •Drug Treatment
- •Bronchodilators
- •mTOR Inhibitors
- •Anti-Oestrogen Therapy
- •Experimental Therapies
- •Interventions for Advanced Disease
- •Oxygen Therapy
- •Pulmonary Hypertension
- •References
- •20: Diffuse Cystic Lung Disease
- •Introduction
- •Lymphangioleiomyomatosis
- •Pathogenesis
- •Pathologic and Radiographic Characteristics
- •Diagnostic Approach
- •Pulmonary Langerhans Cell Histiocytosis (PLCH)
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Birt-Hogg-Dubé Syndrome (BHD)
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Lymphoproliferative Disorders
- •Pathogenesis
- •Pathological and Radiographic Characteristics
- •Diagnostic Approach
- •Amyloidosis
- •Light Chain Deposition Disease (LCDD)
- •Conclusion
- •References
- •Introduction
- •Lymphatic Development
- •Clinical Presentation of Lymphatic Disorders
- •Approaches to Diagnosis and Management of Congenital Lymphatic Anomalies
- •Generalized Lymphatic Anomaly
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Course/Prognosis
- •Management
- •Kaposiform Lymphangiomatosis
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Gorham Stout Disease
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Channel-Type LM/Central Conducting LM
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Yellow Nail Syndrome
- •Etiopathogenesis
- •Clinical Presentation and Diagnosis
- •Management
- •Course/Prognosis
- •Summary
- •References
- •Introduction
- •Historical Note
- •Epidemiology
- •Pathogenesis
- •Surfactant Homeostasis in PAP
- •GM-CSF Signaling Disruption
- •Myeloid Cell Dysfunction
- •GM-CSF Autoantibodies
- •Lymphocytosis
- •Clinical Manifestations
- •Clinical Presentation
- •Secondary Infections
- •Pulmonary Fibrosis
- •Diagnosis
- •Pulmonary Function Testing
- •Radiographic Assessment
- •Bronchoscopy and Bronchoalveolar Lavage
- •Laboratory Studies and Biomarkers
- •GM-CSF Autoantibodies
- •Genetic Testing
- •Lung Pathology
- •Diagnostic Approach to the Patient with PAP
- •Natural History and Prognosis
- •Treatment
- •Whole-Lung Lavage
- •Subcutaneous GM-CSF
- •Inhaled GM-CSF
- •Other Approaches
- •Conclusions and Future Directions
- •References
- •Introduction
- •Epidemiology
- •Gastric Contents
- •Pathobiology of GER/Microaspirate in the Lungs of Patients with IPF
- •GER and the Microbiome
- •Diagnosis
- •Clinical History/Physical Exam
- •Investigations
- •Esophageal Physiology
- •Upper Esophageal Sphincter
- •Esophagus and Peristalsis
- •Lower Esophageal Sphincter and Diaphragm
- •Esophageal pH and Impedance Testing
- •High Resolution Esophageal Manometry
- •Esophagram/Barium Swallow
- •Bronchoalveolar Lavage/Sputum: Biomarkers
- •Treatment
- •Anti-Acid Therapy (PPI/H2 Blocker)
- •GER and Acute Exacerbations of IPF
- •Suggested Approach
- •Summary and Future Directions
- •References
- •Introduction
- •Familial Interstitial Pneumonia
- •Telomere Related Genes
- •Genetic
- •Telomere Length
- •Pulmonary Involvement
- •Interstitial Lung Disease
- •Other Lung Disease
- •Hepatopulmonary Syndrome
- •Emphysema
- •Extrapulmonary Manifestations
- •Mucocutaneous Involvement
- •Hematological Involvement
- •Liver Involvement
- •Other Manifestations
- •Treatment
- •Telomerase Complex Agonists
- •Lung Transplantation
- •Surfactant Pathway
- •Surfactant Protein Genes
- •Pulmonary Involvement
- •Treatment
- •Heritable Forms of Pulmonary Fibrosis with Autoimmune Features
- •TMEM173
- •COPA
- •Pulmonary Alveolar Proteinosis
- •GMCSF Receptor Mutations
- •GATA2
- •MARS
- •Lysinuric Protein Intolerance
- •Lysosomal Diseases
- •Hermansky-Pudlak Syndrome
- •Lysosomal Storage Disorders
- •FAM111B, NDUFAF6, PEPD
- •Conclusion
- •References
- •Introduction
- •Pathophysiology
- •Clinical Presentation
- •Epidemiology
- •Genetic Causes of Bronchiectasis
- •Disorders of Mucociliary Clearance
- •Cystic Fibrosis
- •Primary Ciliary Dyskinesia
- •Other Ciliopathies
- •X-Linked Agammaglobulinemia
- •Chronic Granulomatous Disease and Other Disorders of Neutrophil Function
- •Other Genetic Disorders Predisposing to Bronchiectasis
- •Idiopathic Bronchiectasis
- •Diagnosis of Bronchiectasis
- •Management of Patients with Bronchiectasis
- •Airway Clearance Therapy (ACT)
- •Management of Infections
- •Immune Therapy
- •Surgery
- •Novel Therapies for Managing Cystic Fibrosis
- •Summary
- •References
- •Pulmonary Arteriovenous Malformations
- •Background Pulmonary AVMs
- •Anatomy Pulmonary AVMs
- •Clinical Presentation of Pulmonary AVMs
- •Screening Pulmonary AVMs
- •Treatment Pulmonary AVMs
- •Children with Hereditary Hemorrhagic Telangiectasia
- •Pulmonary Hypertension
- •Pulmonary Hypertension Secondary to Liver Vascular Malformations
- •Pulmonary Arterial Hypertension
- •Background HHT
- •Pathogenesis
- •References
- •27: Pulmonary Alveolar Microlithiasis
- •Introduction
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Diagnosis
- •Management
- •Summary
- •References
- •Introduction
- •Hermansky-Pudlak Syndrome
- •Telomerase-Associated Pulmonary Fibrosis
- •Lysosomal Storage Diseases
- •Lysinuric Protein Intolerance
- •Familial Hypocalciuric Hypercalcemia
- •Surfactant Dysfunction Disorders
- •Concluding Remarks
- •References
- •Introduction
- •Background
- •Image Acquisition
- •Key Features of Fibrosis
- •Ancillary Features of Fibrosis
- •Other Imaging Findings in FLD
- •Probable UIP-IPF
- •Indeterminate
- •Alternative Diagnosis
- •UIP in Other Fibrosing Lung Diseases
- •Pleuroparenchymal Fibroelastosis (PPFE)
- •Combined Pulmonary Fibrosis and Emphysema
- •Chronic Hypersensitivity Pneumonitis
- •Other Fibrosing Lung Diseases
- •Fibrosing Sarcoidosis
- •CTD-ILD and Drug-Induced FLD
- •Complications
- •Prognosis
- •Computer Analysis of CT Imaging
- •The Progressive Fibrotic Phenotype
- •Other Imaging Techniques
- •Conclusion
- •References
- •Introduction
- •Bronchoalveolar Lavage (BAL)
- •Technique
- •Interpretation
- •Transbronchial Biopsy (TBB)
- •Transbronchial Lung Cryobiopsy (TLCB)
- •References
- •Introduction
- •Overview of ILD Diagnosis
- •Clinical Assessment
- •Radiological Assessment
- •Laboratory Assessment
- •Integration of Individual Features
- •Multidisciplinary Discussion
- •Diagnostic Ontology
- •Conclusions
- •References
- •Introduction
- •Idiopathic Pulmonary Fibrosis
- •Chronic Hypersensitivity Pneumonitis
- •Connective Tissue Disease
- •Drug-Induced Lung Diseases
- •Radiation Pneumonitis
- •Asbestosis
- •Hermansky-Pudlak Syndrome
- •Risk Factors for Progression
- •Diagnosis
- •Pharmacological Management
- •Conclusions
- •References
- •Historical Perspective
- •Epidemiology and Etiologies
- •Tobacco Smoking and Male Sex
- •Genetic Predisposition
- •Systemic Diseases
- •Other Etiological Contexts
- •Clinical Manifestations
- •Pulmonary Function and Physiology
- •Imaging
- •Computed Tomography Characteristics and Patterns
- •Thick-Walled Large Cysts
- •Imaging Phenotypes
- •Pitfalls
- •Pathology
- •Diagnosis
- •CPFE Is a Syndrome
- •Biology
- •Complications and Outcome
- •Mortality
- •Pulmonary Hypertension
- •Lung Cancer
- •Acute Exacerbation of Pulmonary Fibrosis
- •Other Comorbidities and Complications
- •Management
- •General Measures and Treatment of Emphysema
- •Treatment of Pulmonary Fibrosis
- •Management of Pulmonary Hypertension
- •References
- •Acute Interstitial Pneumonia (AIP)
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Desquamative Interstitial Pneumonia (DIP)
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •Epidemiology
- •Presentation
- •Diagnostic Evaluation
- •Radiology
- •Histopathology
- •Clinical Course
- •Treatment
- •References
- •Organizing Pneumonias
- •Epidemiology
- •Pathogenesis
- •Clinical Features
- •Imaging
- •Multifocal Form
- •Isolated Nodular Form
- •Other Imaging Patterns
- •Histopathological Diagnosis of OP Pattern
- •Etiological Diagnosis of OP
- •Treatment
- •Clinical Course and Outcome
- •Severe Forms of OP with Respiratory Failure
- •Acute Fibrinous and Organizing Pneumonia
- •Granulomatous Organizing Pneumonia
- •Acute Interstitial Pneumonia
- •Epidemiology
- •Clinical Picture
- •Imaging
- •Histopathology
- •Diagnosis
- •Treatment
- •Outcome
- •References
- •36: Pleuroparenchymal Fibroelastosis
- •Introduction
- •Epidemiology
- •Clinical Manifestations
- •Laboratory Findings
- •Respiratory Function
- •Radiologic Features
- •Pathologic Features
- •Diagnosis
- •Treatment
- •Prognosis
- •Conclusions
- •References
- •Introduction
- •Acute Berylliosis
- •Chronic Beryllium Disease
- •Exposure
- •Epidemiology
- •Immunopathogenesis and Pathology
- •Genetics
- •Clinical Description and Natural History
- •Treatment and Monitoring
- •Indium–Tin Oxide-Lung Disease
- •Hard Metal Lung
- •Flock Worker’s Disease
- •Asbestosis
- •Nanoparticle Induced ILD
- •Flavoring-Induced Lung Disease
- •Silica-Induced Interstitial Lung Disease
- •Chronic Silicosis
- •Acute and Accelerated Silicosis
- •Chronic Obstructive Disease in CMDLD
- •Simple CMDLD
- •Complicated CMDLD
- •Conclusion
- •References
- •38: Unclassifiable Interstitial Lung Disease
- •Introduction
- •Diagnostic Scenarios
- •Epidemiology
- •Clinical Presentation
- •Diagnosis
- •Clinical Features
- •Radiology
- •Laboratory Investigations
- •Pathology
- •Conclusion
- •References
- •39: Lymphoproliferative Lung Disorders
- •Introduction
- •Nodular Lymphoid Hyperplasia
- •Lymphocytic Interstitial Pneumonia (LIP)
- •Follicular Bronchitis/Bronchiolitis
- •Castleman Disease
- •Primary Pulmonary Lymphomas
- •Primary Pulmonary MALT B Cell Lymphoma
- •Pulmonary Plasmacytoma
- •Follicular Lymphoma
- •Lymphomatoid Granulomatosis
- •Primary Pulmonary Hodgkin Lymphoma (PPHL)
- •Treatment
- •References
- •Introduction
- •Late-Onset Pulmonary Complications
- •Bronchiolitis Obliterans (BO)
- •Pathophysiology
- •Diagnosis
- •Management of BOS
- •Post-HSCT Organizing Pneumonia
- •Other Late-Onset NonInfectious Pulmonary Complications (LONIPCs)
- •Conclusion
- •References
- •Introduction
- •Pulmonary Hypertension Associated with Sarcoidosis (Group 5.2)
- •PH Associated with Pulmonary Langerhans Cell Histiocytosis (Group 5.2)
- •PH in Combined Pulmonary Fibrosis and Emphysema (Group 3.3)
- •PH Associated with Lymphangioleiomyomatosis (Group 3)
- •Hereditary Hemorrhagic Telangiectasia (Group 1.2)
- •Pulmonary Veno-Occlusive Disease (Group 1.5)
- •Small Patella Syndrome (Group 1.2)
- •Conclusion
- •References
- •Introduction
- •Epidemiology
- •Timing, Chronology, Delay Time
- •Route of Administration
- •Patterns of Involvement [3, 4]
- •Drugs and Agents Fallen Out of Favor
- •Drug-Induced Noncardiac Pulmonary Edema
- •Drug-Induced Cardiogenic Pulmonary Edema
- •The “Chemotherapy Lung”
- •Drug-Induced/Iatrogenic Alveolar Hemorrhage
- •Drugs
- •Superwarfarin Rodenticides
- •Transfusion Reactions: TACO–TRALI
- •Acute Eosinophilic Pneumonia
- •Acute Granulomatous Interstitial Lung Disease
- •Acute Organizing Pneumonia (OP), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), or Acute Fibrinous Organizing Pneumonia (AFOP) Patterns
- •Acute Amiodarone-Induced Pulmonary Toxicity (AIPT)
- •Accelerated Pulmonary Fibrosis
- •Acute Exacerbation of Previously Known (Idiopathic) Pulmonary Fibrosis
- •Anaphylaxis
- •Acute Vasculopathy
- •Drug-Induced/Iatrogenic Airway Emergencies
- •Airway Obstruction as a Manifestation of Anaphylaxis
- •Drug-Induced Angioedema
- •Hematoma Around the Upper Airway
- •The “Pill Aspiration Syndrome”
- •Catastrophic Drug-Induced Bronchospasm
- •Peri-operative Emergencies (Table 42.8)
- •Other Rare Presentations
- •Pulmonary Nodules and Masses
- •Pleuroparenchymal Fibroelastosis
- •Late Radiation-Induced Injury
- •Chest Pain
- •Rebound Phenomenon
- •Recall Pneumonitis
- •Thoracic Bezoars: Gossipybomas
- •Respiratory Diseases Considered Idiopathic That May Be Drug-Induced (Table 42.4)
- •Eye Catchers
- •Conclusion
- •References
- •Cancer Mimics of Organizing Pneumonia
- •Lung Adenocarcinoma/Bronchioloalveolar Carcinoma
- •Primary Pulmonary Lymphoma
- •Cancer Mimics of Interstitial Lung Diseases
- •Lymphangitic Carcinomatosis
- •Epithelioid Hemangio-Endothelioma
- •Lymphomatoid Granulomatosis
- •Cystic Tumors
- •Cavitating Tumors
- •Intrathoracic Pseudotumors
- •Respiratory Papillomatosis
- •Pulmonary Langerhans Cell Histiocytosis
- •References
- •Index
498 |
|
|
|
P. Spagnolo and N. Bernardinello |
|
|
|
|
|
|
|
Table 28.2 (continued) |
|
|
|
|
|
|
|
|
|
|
|
|
Age of onset of |
|
|
Diagnosis |
|
|
pulmonary |
Mode of |
Extrapulmonary |
|
|
Disease |
manifestations |
presentation |
manifestations |
Suggestive features |
Con rmatory tests |
Familial |
Variable |
Granulomatous |
Chondrocalcinosis |
Hypocalciuria |
24-h urine calcium/ |
hypocalciuric |
|
lung disease |
|
|
creatinine clearance |
hypercalcemia |
|
|
|
|
ratio |
|
|
|
|
|
|
|
|
Pulmonary |
Acute pancreatitis |
Hypercalcemia |
Genetic testing |
|
|
brosis |
|
|
|
|
|
|
|
No signs or symptoms |
|
|
|
|
|
of primary |
|
|
|
|
|
hyperparathyroidism |
|
Neuro bromatosis |
Fourth to sixth |
Pulmonary |
Neurological |
Café-au-lait spots, |
Genetic testing |
Type 1 |
decade |
brosis (lower |
involvement |
axillary and inguinal |
|
|
|
zones) |
|
freckling |
|
|
|
|
|
|
|
|
|
Bullous changes |
Optic gliomas |
Lisch nodules |
|
|
|
(upper zones) |
|
|
|
|
|
Pulmonary |
Osseous lesions |
|
|
|
|
neuro bromas |
|
|
|
|
|
|
|
|
|
|
|
Pulmonary |
Cutaneous |
|
|
|
|
hypertension |
neuro bromas |
|
|
Surfactant |
Birth-childhood |
Respiratory |
Variable (depending on |
Variable (depending on |
Genetic testing |
dysfunction |
|
distress |
the speci c disease) |
the speci c disease) |
|
disordersa |
|
syndrome |
|
|
|
|
|
Interstitial lung |
|
|
|
|
|
disease |
|
|
|
a See also Table 28.1 |
|
|
|
|
|
Table 28.3 Radiographic patterns of lung involvement on high- resolution computed tomography
Disease |
Radiographic pattern |
Hermansky-Pudlak |
Diffuse, peripheral reticulation; subpleural |
syndrome |
cysts; ground glass opacity, |
|
peribronchovascular thickening; |
|
bronchiectasis |
|
|
Dyskeratosis |
Subpleural bibasal honeycombing, traction |
congenita |
bronchiectasis, reticular opacities |
Gaucher’s disease |
Reticular changes, ground glass opacities |
Nieman-Pick Type |
Ground glass opacities with an upper lobe |
disease |
predominance, and basilar predominant |
|
interlobular septal thickening |
Fabry’s disease |
Diffuse ground glass and mosaic |
|
attenuation |
|
|
Lysinuric protein |
Ground glass opacities superimposed over a |
intolerance |
pattern of ne overlapping lines forming |
|
irregular polygonal shapes (“crazy paving”) |
Familial |
Reticulo-nodular in ltrates, honeycombing |
hypocalciuric |
|
hypercalcemia |
|
Neuro bromatosis |
Bibasilar (usually symmetrical) reticular |
Type 1 |
changes, ground glass opacities, upper lobe |
|
predominant (usually asymmetrical) small |
|
cysts, and thin-walled bullae |
Surfactant |
Diffuse ground glass opacities, septal |
dysfunction disorders |
thickening, parenchymal cysts |
|
|
References
1.\Thomas AQ, Lane K, Phillips J III, Prince M, Markin C, Speer M, et al. Heterozygosity for a surfactant protein c gene mutation associated with usual interstitial pneumonitis and cellular nonspeci c interstitial pneumonitis in one kindred. Am J Respir Crit Care Med. 2002;165:1322–8.
2.\Nogee LM, Dunbar AE III, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med. 2001;344:573–9.
3.\Lawson WE, Grant SW, Ambrosini V, Womble KE, Dawson EP, Lane KB, et al. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax. 2004;59:977–80.
4.\Wang Y, Kuan PJ, Xing C, Cronkhite JT, Torres F, Rosenblatt RL, et al. Genetic defects in surfactant protein A2 are associated with pulmonary brosis and lung cancer. Am J Hum Genet. 2009;84:52–9.
5.\Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, et al. Telomerase mutations in families with idiopathic pulmonary brosis. N Engl J Med. 2007;356:1317–26.
6.\Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, et al. Adult-onset pulmonary brosis caused by mutations in telomerase. Proc Natl Acad Sci U S A. 2007;104:7552–7.
7.\Diaz de Leon A, Cronkhite JT, Katzenstein AL, Godwin JD, Raghu G, Glazer CS, et al. Telomere lengths, pulmonary brosis and telomerase (TERT) mutations. PLoS One. 2010;5:e10680.
8.\Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, et al. A common MUC5B promoter polymorphism and pulmonarybrosis. N Engl J Med. 2011;364:1503–12.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
28 Rare Difuse Lung Diseases of Genetic Origin |
499 |
|
|
9.\Steele MP, Speer MC, Loyd JE, Brown KK, Herron A, Slifer SH, et al. Clinical and pathological features of familial interstitial pneumonia. Am J Respir Crit Care Med. 2005;172:1146–52.
10.\Hermansky F, Pudlak P. Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow: report of two cases with histochemical studies. Blood. 1959;14:162–9.
11.\Huizing M, Helip-Wooley A, Westbroek W, Gunay-Aygun M, Gahl WA. Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu Rev Genomics Hum Genet. 2008;9:359–86.
12.\Wei ML. Hermansky-Pudlak syndrome: a disease of protein traf-cking and organelle function. Pigment Cell Res. 2006;19:19–42.
13.\Wildenberg SC, Oetting WS, Almodóvar C, Krumwiede M, White JG, King RA. Am J Hum Genet. 1995;57:755–65.
14.\Gahl WA, Brantly M, Kaiser-Kupfer MI, Iwata F, Hazelwood S, Shotelersuk V, et al. I. Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky- Pudlak syndrome). N Engl J Med. 1998;338:1258–65.
15.\Witkop CJ, Krumwiede M, Sedano H, White JG. Reliability of absent platelet dense bodies as a diagnostic criterion for HermanskyPudlak syndrome. Am J Hematol. 1987;26:305–11.
16.\Di Pietro SM, Dell’Angelica EC. The cell biology of Hermansky- Pudlak syndrome: recent advances. Traf c. 2005;6:525–33.
17.\Seward SL Jr, Gahl WA. Hermansky-Pudlak syndrome: health care throughout life. Pediatrics. 2013;132:153–60.
18.\El-Chemaly S, Young LR. Hermansky-Pudlak Syndrome. Clin Chest Med. 2016;37:505–11.
19.\Brantly M, Anderson PD, Parker MS, Rosado Shipley W, de Christenson ML, Slutzker AD, Carroll FE, Worrell JA, White JG. The Hermansky-Pudlak syndrome. Ann Diagn Pathol. 1997;1:99–103.
20.\Hengst M, Naehrlich L, Mahavadi P, Grosse-Onnebrink J, Terheggen-Lagro S, Skanke LH, et al. Hermansky-Pudlak syndrome type 2 manifests with brosing lung disease early in childhood. Orphanet J Rare Dis. 2018;13:42.
21.\Mahavadi P, Korfei M, Henneke I, Liebisch G, Schmitz G, Gochuico BR, et al. Epithelial stress and apoptosis underlie HermanskyPudlak syndrome-associated interstitial pneumonia. Am J Respir Crit Care Med. 2010;182:207–19.
22.\Avila NA, Brantly M, Premkumar A, et al. Hermansky-Pudlak syndrome: radiography and CT of the chest compared with pulmonary function tests and genetic studies. Am J Roentgenol. 2002;179:887–92.
23.\Nakatani Y, Nakamura N, Sano J, Inayama Y, Kawano N, Yamanaka S, et al. Interstitial pneumonia in Hermansky-Pudlak syndrome: signi cance of forid foamy swelling/degeneration (giant lamellar body degeneration) of type-2 pneumocytes. Virchows Arch. 2000;437:304–13.
24.\El-Chemaly S, O’Brien KJ, Nathan SD, Weinhouse GL, Goldberg HJ, Connors JM, et al. Clinical management and outcomes of patients with Hermansky-Pudlak syndrome pulmonary brosis evaluated for lung transplantation. PLoS One. 2018;13:e0194193.
25.\Gahl WA, Brantly M, Troendle J, Avila NA, Padua A, Montalvo C, Cardona H, Calis KA, Gochuico B. Effect of pirfenidone on the pulmonary brosis of Hermansky-Pudlak syndrome. Mol Genet Metabol. 2002;76:234–42.
26.\O’Brien K, Troendle J, Gochuico BR, Markello TC, Salas J, Cardona H, et al. Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary brosis. Mol Genet Metab. 2011;103:128–34.
27.\Morla M, Busquets X, Pons J, Sauleda J, MacNee W, Agusti AG. Telomere shortening in smokers with and without COPD. Eur Respir J. 2006;27:525–8.
28.\Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009;361:2353–65.
29.\Nelson ND, Bertuch AA. Dyskeratosis congenita as a disorder of telomere maintenance. Mutat Res. 2012;730:43–51.
30.\Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol. 2000;110:768–79.
31.\Walne AJ, Vulliamy T, Beswick R, Kirwan M, Dokal I. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood. 2008;112:3594–600.
32.\Armanios M, Chen JL, Chang YP, Brodsky RA, Hawkins A, Grif n CA, et al. Haploinsuf ciency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A. 2005;102:15960–4.
33.\Hoffman TW, van Moorsel CHM, Borie R, Crestani B. Pulmonary phenotypes associated with genetic variation in telomere-related genes. Curr Opin Pulm Med. 2018;24:269–80.
34.\Verra F, Kouzan S, Saiag P, Bignon J, de Cremoux H. Bronchoalveolar disease in dyskeratosis congenita. Eur Respir J. 1992;5:497–9.
35.\Cronkhite JT, Xing C, Raghu G, Chin KM, Torres F, Rosenblatt RL, et al. Telomere shortening in familial and sporadic pulmonarybrosis. Am J Respir Crit Care Med. 2008;178:729–37.
36.\Newton CA, Batra K, Torrealba J, Kozlitina J, Glazer CS, Aravena C, et al. Telomere-related lung brosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J. 2016;48:1710–20.
37.\Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, Cogan JD, et al. Short telomeres are a risk factor for idiopathic pulmonary brosis. Proc Natl Acad Sci U S A. 2008;105:13051–6.
38.\Liu S, Wang C, Green G, Zhuo H, Liu KD, Kangelaris KN, et al. Peripheral blood leukocyte telomere length is associated with survival of sepsis patients. Eur Respir J. 2020;55(1):1901044. https:// doi.org/10.1183/13993003.01044-2019.
39.\Luu HN, Huang JY, Wang R, Adams-Haduch J, Jin A, Koh WP, et al. Association between leukocyte telomere length and the risk of pancreatic cancer: ndings from a prospective study. PLoS One. 2019;14:e0221697.
40.\Tian Y, Wang S, Jiao F, Kong Q, Liu C, Wu Y. Telomere length: a potential biomarker for the risk and prognosis of stroke. Front Neurol. 2019;10:624.
41.\Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. J Am Med Assoc. 1999;281:249–54.
42.\Campbell TN, Choy FY. Gaucher disease and the synucleinopathies: re ning the relationship. Orphanet J Rare Dis. 2012;7:12.
43.\Nalysnyk L, Rotella P, Simeone JC, Hamed A, Weinreb N. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology. 2017;22:65–73.
44.\Zimran A, Gelbart T, Westwood B, Grabowski GA, Beutler E. High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews. Am J Hum Genet. 1991;49:855–9.
45.\Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet. 2008;372:1263–71.
46.\Hruska KS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat. 2008;29:567–83.
47.\Beutler E, Gelbart T, Scott CR. Hematologically important mutations: Gaucher disease. Blood Cell Mol Dis. 2005;35:355–64.
48.\Harmanci O, Bayraktar Y. Gaucher disease: new developments in treatment and etiology. World J Gastroenterol. 2008;14:3968–73.
49.\Miller A, Brown LK, Pastores GM, Desnick RJ. Pulmonary involvement in type 1 Gaucher disease: functional and exercise ndings in patients with and without clinical interstitial lung disease. Clin Genet. 2003;63:368–76.
50.\Kerem E, Elstein D, Abrahamov A, Bar Ziv Y, Hadas-Halpern I, Melzer E, et al. Pulmonary function abnormalities in type I Gaucher disease. Eur Respir J. 1996;9:340–5.
51.\Beutler E. Gaucher’s disease. N Engl J Med. 1991;325:1354–60.
500 |
P. Spagnolo and N. Bernardinello |
|
|
52.\Santamaria F, Parenti G, Guidi G, Filocamo M, Strisciuglio P, Grillo G, et al. Pulmonary manifestations of Gaucher disease: an increased risk for L444P homozygotes? Am J Respir Crit Care Med. 1998;157:985–9.
53.\Mistry PK, Sirrs S, Chan A, Pritzker MR, Duffy TP, Grace ME, Meeker DP, Goldman ME. Pulmonary hypertension in type 1 Gaucher’s disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab. 2002;77:91–8.
54.\Gupta P, Pastores G. Pharmacological treatment of pediatric Gaucher disease. Expert Rev Clin Pharmacol. 2018;11:1183–94.
55.\Goitein O, Elstein D, Abrahamov A, Hadas-Halpern I, Melzer E, Kerem E, Zimran A. Lung involvement and enzyme replacement therapy in Gaucher’s disease. QJM. 2001;94:407–15.
56.\van Dussen L, Hendriks EJ, Groener JE, Boot RG, Hollak CE, Aerts JM. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy. J Inherit Metab Dis. 2014;37:991–1001.
57.\de Boer GM, van Dussen L, van den Toorn LM, den Bakker MA, Hoek RA, Hesselink DA, et al. Lung transplantation in Gaucher disease: a learning lesson in trying to avoid both Scylla and Charybdis. Chest. 2016;149:e1–5.
58.\Schuchman EH. The pathogenesis and treatment of acid sphingomyelinase-de cient Niemann-Pick disease. J Inherit Metab Dis. 2007;30:654–63.
59.\Levran O, Desnick RJ, Schuchman EH. Niemann-Pick type B disease: identi cation of a single codon deletion in the acid sphingomyelinase gene and genotype/phenotype correlations in type A and B patients. J Clin Invest. 1991;88:806–10.
60.\Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281:249–54.
61.\Vanier MT. Nieman-Pick disease type C. Orphanet J Rare Dis. 2010;5:16.
62.\Sleat DE, Wiseman JA, El Banna M, Price SM, Verot L, Shen MM, Tint GS, Vanier MT, Walkley SU, Lobel P. Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport. Proc Natl Acad Sci U S A. 2004;101:5886–91.
63.\Kwon HJ, Abi-Mosleh L, Wang ML, Deisenhofer J, Goldstein JL, Brown MS, Infante RE. Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol. Cell. 2009;137:1213–24.
64.\Millat G, Chikh K, Naureckiene S, Sleat DE, Fensom AH, Higaki K, Elleder M, Lobel P, Vanier MT. Niemann-Pick disease type C: spectrum of HE1 mutations and genotype/phenotype correlations in the NPC2 group. Am J Hum Genet. 2001;69:1013–21.
65.\Guillemot N, Troadec C, de Villemeur TB, Clément A, Fauroux B. Lung disease in Niemann-Pick disease. Pediatr Pulmonol. 2007;42:1207–14.
66.\Mendelson DS, Wasserstein MP, Desnick RJ, Glass R, Simpson W, Skloot G, et al. Type B Niemann-Pick disease: ndings at chest radiography, thin-section CT, and pulmonary function testing. Radiology. 2006;238:339–45.
67.\Griese M, Brasch F, Aldana VR, Cabrera MM, Goelnitz U, Ikonen E, et al. Respiratory disease in Niemann-Pick type C2 is caused by pulmonary alveolar proteinosis. Clin Genet. 2010;77:119–30.
68.\Nicholson AG, Florio R, Hansell DM, du Bois RM, Wells AU, Hughes P, et al. Pulmonary involvement by Niemann-Pick disease. A report of six cases. Histopathology. 2006;48:596–603.
69.\Uyan ZS, Karadağ B, Ersu R, Kiyan G, Kotiloğlu E, Sirvanci S, et al. Early pulmonary involvement in Niemann-Pick type B disease: lung lavage is not useful. Pediatr Pulmonol. 2005;40:169–72.
70.\O’Neill RS, Belousova N, Malouf MA. Pulmonary type B Niemann-Pick disease successfully treated with lung transplantation. Case Rep Transplant. 2019;2019:9431751.
71.\Clarke JT. Narrative review: Fabry disease. Ann Intern Med. 2007;146:425–33.
72.\Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural history of Fabry renal disease: infuence of α-galactosidase A activity and genetic mutations on clinical course. Medicine. 2002;81:122–38.
73.\Shirai T, Ohtake T, Kimura M, Iwata M, Fujigaki Y, Takayanagi S, Chida K, Nakamura H, Hishida A, Irie F. Atypical Fabry’s disease presenting with cholesterol crystal embolization. Intern Med. 2000;39:646–9.
74.\Magage S, Lubanda JC, Susa Z, Bultas J, Karetová D, Dobrovolný R, Hrebícek M, Germain DP, Linhart A. Natural history of the respiratory involvement in Anderson-Fabry disease. J Inherit Metab Dis. 2007;30:790–9.
75.\Franzen DP, Nowak A, Haile SR, Mottet D, Bonani M, Dormond O, et al. Long-term follow-up of pulmonary function in Fabry disease: a bi-center observational study. PLoS One. 2017;12:e0180437.
76.\Koskenvuo JW, Kantola IM, Nuutila P, Knuuti J, Parkkola R, Mononen I, et al. Cardiopulmonary involvement in Fabry’s disease. Acta Cardiol. 2010;65:185–92.
77.\McCafferty EH, Scott LJ. Migalastat: a review in Fabry disease. Drugs. 2019;79:543–54.
78.\Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: a systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019;19:100454.
79.\Magage S, Lubanda JC, Susa Z, Bultas J, Karetová D, Dobrovolný R, et al. Natural history of the respiratory involvement in AndersonFabry disease. J Inherit Metab Dis. 2007;30:790–9.
80.\Simell O, Perheentupa J, Rapola J, Visakorpi JK, Eskelin LE. Lysinuric protein intolerance. Am J Med. 1975;59:229–40.
81.\Mykkanen J, Torrents D, Pineda M, Camps M, Yoldi ME, Horelli- Kuitunen N, et al. Functional analysis of novel mutations in y(þ) LAT-1 amino acid transporter gene causing lysinuric protein intolerance (LPI). Hum Mol Genet. 2000;9:431–8.
82.\Koizumi A, Shoji Y, Nozaki J, Noguchi A, X E, Dakeishi M, et al. A cluster of lysinuric protein intolerance (LPI) patients in a northern part of Iwate, Japan due to a founder effect. The Mass Screening Group. Hum Mutat. 2000;16:270–1.
83.\Parto K, Svedstrom E, Majurin ML, Härkönen R, Simell O. Pulmonary manifestations in lysinuric protein intolerance. Chest. 1993;104:1176–82.
84.\Mauhin W, Habarou F, Gobin S, Servais A, Brassier A, Grisel C, et al. Update on lysinuric protein intolerance, a multi-faceted disease retrospective cohort analysis from birth to adulthood. Orphanet J Rare Dis. 2017;12:3.
85.\Ceruti M, Rodi G, Stella GM, Adami A, Bolongaro A, Baritussio A, Pozzi E, Luisetti M. Successful whole lung lavage in pulmonary alveolar proteinosis secondary to lysinuric protein intolerance: a case report. Orphanet J Rare Dis. 2007;2:14.
86.\Tanner LM, Kurko J, Tringham M, Aho H, Mykkänen J, Näntö- Salonen K, et al. Inhaled sargramostim induces resolution of pulmonary alveolar proteinosis in lysinuric protein intolerance. JIMD Rep. 2017;34:97–104.
87.\Auwerx J, Demedts M, Bouillon R, Desmet J. Coexistence of hypocalciuric hypercalcaemia and interstitial lung disease in a family: a cross-sectional study. Eur J Clin Investig. 1985;15:6–14.
88.\Lee JY, Shoback DM. Familial hypocalciuric hypercalcemia and related disorders. Best Pract Res Clin Endocrinol Metab. 2018;32(5):609–19.
89.\Pearce SHS, Wooding C, Davies M, Tollefsen SE, Whyte MP, Thakker RV. Calcium-sensing receptor mutations in familial
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
28 Rare Difuse Lung Diseases of Genetic Origin |
501 |
|
|
hypocalciuric hypercalcaemia with recurrent pancreatitis. Clin Endocrinol. 1996;45:675–80.
90.\Volpe A, Guerriero A, Marchetta A, Caramaschi P, Furlani L. Familial hypocalciuric hypercalcaemia revealed by chondrocalcinosis. Joint Bone Spine. 2009;76:708–10.
91.\Demedts M, Auwerx J, Goddeeris P, Bouillon R, Gyselen A, Lauweryns J. The inherited association of interstitial lung disease, hypocalciuric hypercalcemia, and defective granulocyte function. Am Rev Respir Dis. 1985;131:470–5.
92.\Riccardi VM. Von Recklinghausen neuro bromatosis. N Engl J Med. 1981;305:1617–27.
93.\Neuro bromatosis: conference statement: National Institutes of Health Consensus Development Conference. Arch Neurol. 1988;45:575–8.
94.\Evans DG, Baser ME, McGaughran J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neuro bromatosis 1. J Med Genet. 2002;39:311–4.
95.\Zamora AC, Collard HR, Wolters PJ, Webb WR, King TE. Neuro bromatosis-associated lung disease: a case series and literature review. Eur Respir J. 2007;29:210–4.
96.\Reviron-Rabec L, Girerd B, Seferian A, Campbell K, Brosseau S, Bergot E, et al. Pulmonary complications of type 1 neuro bromatosis. Rev Mal Respir. 2016;33:460–73.
97.\Massaro D, Katz S. Fibrosing alveolitis: its occurrence, roentgenographic, and pathologic features in von Recklinghausen’s neuro-bromatosis. Am Rev Respir Dis. 1966;93:934–42.
98.\Chang ET, Hu WangA, Lin CB, Lee JJ,Yang GG. Pulmonary manifestation in neuro bromatosis type 1. Intern Med. 2007;46:527–8.
99.\Ueda K, Honda O, Satoh Y, Kawai M, Gyobu T, Kanazawa T, et al. Computed tomography (CT) ndings in 88 neuro bromatosis 1 (NF1) patients: prevalence rates and correlations of thoracic ndings. Eur J Radiol. 2015;84:1191–5.
100.\Riccardi VM, Lewis RA. Penetrance of von Recklinghausen neuro bromatosis: a distinction between predecessors and descendants. Am J Hum Genet. 1998;42:284–9.
101.\Montani D, Coulet F, Girerd B, Eyries M, Bergot E, Mal H, et al. Pulmonary hypertension in patients with neuro bromatosis type I. Medicine. 2011;90:201–11.
102.\Jutant EM, Girerd B, Jaïs X, Savale L, O’Connell C, Perros F, et al. Pulmonary hypertension associated with neuro bromatosis type 1. Eur Respir Rev. 2018;27:180053.
103.\De Scheerder I, Elinck W, Van Renterghem D, Cuvelier C, Tasson J, Van der Straeten M. Desquamative interstitial pneumonia and scar cancer of the lung complicating generalised neuro bromatosis. Eur J Respir Dis. 1984;65:623–6.
104.\Shimizu Y, Tsuchiya S, Watanabe S, Saitoh R. von Recklinghausen’s disease with lung cancer derived from the wall of emphysematous bullae. Intern Med. 1994;33:167–71.
105.\Huie TJ, Schwarz MI. Miscellaneous interstitial lung diseases. In: Schwarz MI, King TE, editors. Interstitial lung disease. London: BC Decker Inc.; 2011.
106.\Garmany TH, Wambach JA, Heins HB, Watkins-Torry JM, Wegner DJ, Bennet K, et al. Population and disease-based prevalence of the common mutations associated with surfactant de - ciency. Pediatr Res. 2008;63:645–9.
107.\Wert SE, Whitsett JA, Nogee LM. Genetic disorders of surfactant dysfunction. Pediatr Dev Pathol. 2009;12:253–74.
108.\Nogee LM, Garnier G, Dietz HC, Singer L, Murphy AM, de Mello DE, Colten HR. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest. 1994;93:1860–3.
109.\Nogee LM, Wert SE, Prof t SA, Hull WM, Whitsett JA. Allelic heterogeneity in hereditary surfactant protein B (SP-B) de ciency. Am J Respir Crit Care Med. 2000;161:973–81.
110.\Dunbar AE III, Wert SE, Ikegami M, Whitsett JA, Hamvas A, White FV, Piedboeuf B, Jobin C, Guttentag S, Nogee LM. Prolonged survival in hereditary surfactant protein B (SP-B) de ciency associated with a novel splicing mutation. Pediatr Res. 2000;48:275–82.
111.\Cameron HS, Somaschini M, Carrera P, Hamvas A, Whitsett JA, Wert SE, Deutsch G, Nogee LM. A common mutation in the surfactant protein C gene associated with lung disease. J Pediatr. 2005;146:370–5.
112.\Guillot L, Epaud R, Thouvenin G, Jonard L, Mohsni A, Couderc R, et al. New surfactant protein C gene mutations associated with diffuse lung disease. J Med Genet. 2009;46:490–4.
113.\Mulugeta S, Nguyen V, Russo SJ, Muniswamy M, Beers MF. A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. Am J Respir Cell Mol Biol. 2005;32:521–30.
114.\Avital A, Hevroni A, Godfrey S, Cohen S, Maayan C, Nusair S, et al. Natural history of ve children with surfactant protein C mutations and interstitial lung disease. Pediatr Pulmonol. 2014;49:1097–105.
115.\van Moorsel CH, van Oosterhout MF, Barlo NP, de Jong PA, van der Vis JJ, Ruven HJ, et al. Surfactant protein C mutations are the basis of a signi cant portion of adult familial pulmonary brosis in a Dutch cohort. Am J Respir Crit Care Med. 2010;182:1419–25.
116.\Markart P, Ruppert C, Wygrecka M, Schmidt R, Korfei M, Harbach H, et al. Surfactant protein C mutations in sporadic forms of idiopathic interstitial pneumonias. Eur Respir J. 2007;29:134–7.
117.\Abou Taam R, Jaubert F, Emond S, Le Bourgeois M, Epaud R, Karila C, et al. Familial interstitial disease with I73T mutation: a midand long-term study. Pediatr Pulmonol. 2009;44:167–75.
118.\Beers MF, Mulugeta S. The biology of theABCA3 lipid transporter in lung health and disease. Cell Tissue Res. 2017;367:481–93.
119.\Kröner C, Wittmann T, Reu S, Teusch V, Klemme M, Rauch D, et al. Lung disease caused by ABCA3 mutations. Thorax. 2017;72:213–20.
120.\Wambach JA, Wegner DJ, Depass K, Heins H, Druley TE, Mitra RD, et al. Single ABCA3 mutations increase risk for neonatal respiratory distress syndrome. Pediatrics. 2012;130:e1575–82.
121.\Bullard JE, Wert SE, Whitsett JA, Dean M, Nogee LM. ABCA3 mutations associated with pediatric interstitial lung disease. Am J Respir Crit Care Med. 2005;172:1026–31.
122.\Doan ML, Guillerman RP, Dishop MK, Nogee LM, Langston C, Mallory GB, et al. Clinical, radiological and pathological features of ABCA3 mutations in children. Thorax. 2008;63:366–73.
123.\Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M. ABCA3 gene mutations in newborns with fatal surfactant de - ciency. N Engl J Med. 2004;350:1296–303.
124.\Wambach JA, Casey AM, Fishman MP, Wegner DJ, Wert SE, Cole FS, et al. Genotype-phenotype correlations for infants and children with ABCA3 de ciency. Am J Respir Crit Care Med. 2014;189:1538–43.
125.\Thavagnanam S, Cutz E, Manson D, et al. Variable clinical outcome of ABCA3 de ciency in two siblings. Pediatr Pulmonol. 2013;48:1035.
126.\Young LR, Nogee LM, Barnett B, Panos RJ, Colby TV, Deutsch GH. Usual interstitial pneumonia in an adolescent with ABCA3 mutations. Chest. 2008;134:192–5.
127.\Krude H, Schutz B, Biebermann H, von Moers A, Schnabel D, Neitzel H, et al. Choreoathetosis, hypothyroidism, and pulmonary alterations due to human NKX2-1 haploinsuf ciency. J Clin Invest. 2002;109:475–80.
128.\Willemsen MA, Breedveld GJ, Wouda S, Otten BJ, Yntema JL, Lammens M, et al. Brain-thyroid-lung syndrome: a patient
502 |
P. Spagnolo and N. Bernardinello |
|
|
with a severe multi-system disorder due to a de novo mutation in the thyroid transcription factor 1 gene. Eur J Pediatr. 2005;164:28–30.
129.\Doyle DA, Gonzalez I, Thomas B, Scavina M. Autosomal dominant transmission of congenital hypothyroidism, neonatal respiratory distress, and ataxia caused by a mutation of NKX2-1. J Pediatr. 2004;145:190–3.
130.\Guillot L, Carre A, Szinnai G, Castanet M, Tron E, Jaubert F, et al. NKX2-1 mutations leading to surfactant protein promoter dysregulation cause interstitial lung disease in “Brain-Lung-Thyroid Syndrome”. Hum Mutat. 2010;31:E1146–62.
131.\Nattes E, Lejeune S, Carsin A, Borie R, Gibertini I, Balinotti J, et al. Heterogeneity of lung disease associated with NK2 homeobox 1 mutations. Respir Med. 2017;129:16–23.
132.\Hamvas A, Deterding RR, Wert SE, White FV, Dishop MK, Alfano DN, et al. Heterogeneous pulmonary phenotypes associated with mutations in the thyroid transcription factor gene NKX2-1. Chest. 2013;144:794–804.
133.\Deutsch GH, Young LR, Deterding RR, Fan LL, Dell SD, Bean JA, et al. Diffuse lung disease in young children: application of a novel classi cation scheme. Am J Respir Crit Care Med. 2007;176:1120–8.
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/
Part VI
Interstitial Lung Diseases, Non Systemic
Imaging Approach to Interstitial Lung |
29 |
Disease |
Teresa M. Jacob, Tahreema N. Matin, and Joseph Jacob
Clinical Vignette
T. M. Jacob
Department of Radiology, St Georges Hospital, London, UK e-mail: Teresa.jacob@stgeorges.nhs.uk
T. N. Matin
Education and Quality, Health Education England, London, UK e-mail: tahreema.matin@hee.nhs.uk
J. Jacob (*)
Department of Respiratory Medicine, Rayne Institute, University College London, London, UK
Centre for Medical Image Computing, University College London, London, UK
e-mail: j.jacob@ucl.ac.uk
A 71-year-old male 100-pack-year ex-smoker presented with a cough to his local hospital. On the initial axial computed tomography (CT) image (left), there was evidence of lower zone predominant brosis in a basal, peripheral and subpleural distribution. Traction bronchiectasis and reticulation were evident in the right lower lobe, but no honeycombing was present. According to the 2011 ATS/ERS/JRS/ALAT consensus guidelines for idiopathic pulmonary brosis, the patient demonstrated a possible usual interstitial pneumonia pattern on CT imaging. The major change to CT categorisation that has resulted following the publication of the 2018 ATS/ERS/JRS/ALAT consensus guidelines for idiopathic pulmonary brosis is that this pattern of lower zone predominant traction bronchiectasis without honeycombing is now classi ed as a probable usual interstitial pneumonia pattern.
The clinical history suggested an idiopathic cause for the brosis and following discussion by a multidisciplinary team the patient was diagnosed with idiopathic pulmonary brosis. The patient did not attend
© Springer Nature Switzerland AG 2023 |
505 |
V. Cottin et al. (eds.), Orphan Lung Diseases, https://doi.org/10.1007/978-3-031-12950-6_29 |
|
Данная книга находится в списке для перевода на русский язык сайта https://meduniver.com/